Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions

Abstract Introduction Spesolimab, a selective, humanised monoclonal antibody targeting the interleukin-36 receptor, is approved for the treatment of generalised pustular psoriasis (GPP). As a result of the limited patient numbers in GPP trials of spesolimab, analysing safety events across dermatolog...

Descripción completa

Detalles Bibliográficos

Autores principales:	Kenneth B. Gordon, Yayoi Tada, Milan J. Anadkat, Siew Eng Choon, Boni Elewski, Jonathan N. Barker, Arash Mostaghimi, Kilian Eyerich, Ming Tang, Thomas Haeufel, Christian Thoma, Diamant Thaçi
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Adis, Springer Healthcare 2025-02-01
Colección:	Dermatology and Therapy
Materias:	Inflammatory skin diseases Spesolimab Biologics Generalised pustular psoriasis GPP Clinical trials
Acceso en línea:	https://doi.org/10.1007/s13555-024-01325-7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!